NASDAQ:MDCO Medicines (MDCO) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free MDCO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$84.90▼$84.9050-Day Range$84.90▼$84.9052-Week Range$17.81▼$84.98VolumeN/AAverage Volume9.55 million shsMarket Capitalization$6.77 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Medicines alerts: Email Address Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Medicines Stock (NASDAQ:MDCO)The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.Read More Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. MDCO Stock News HeadlinesApril 12, 2024 | marketbeat.comNo link between Ozempic, Wegovy and suicide, EU drug regulators sayDrug regulators in Europe have found no evidence that popular diabetes and weight-loss drugs like Ozempic and Wegovy are linked to a higher risk of suicidal thoughts or actionsApril 4, 2024 | reuters.comMitsui and Rohto to buy $594 mln Chinese medicines company Eu Yan SangApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.March 15, 2024 | investorplace.comFIXX Stock Earnings: Homology Medicines Beats EPS for Q4 2023February 23, 2024 | bbc.co.ukMedicine in Britain, c.1250 to the present dayJanuary 4, 2024 | marketwatch.comRevolution Medicines started at outperform with $41 stock price target at WedbushDecember 30, 2023 | dailymail.co.ukWarming on cancer risk in Chinese medicinesDecember 15, 2023 | bbc.comGene modified chickens 'lay medicines'April 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.November 27, 2023 | prnewswire.comAbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular LymphomaOctober 23, 2023 | ft.comEU plans for countries to share medicines in case of shortageOctober 20, 2023 | rttnews.comCVS To Remove Some Cold, Cough Medicines With Phenylephrine October 4, 2023 | bizjournals.comHow Revolution Medicines chased down EQRx's $1 billion cash prizeOctober 4, 2023 | benzinga.comCancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding SharesAugust 21, 2023 | prnewswire.comApproval of an Orphan Disease Application for its lead product, the Cellspan Esophageal Implant by the European Medicines AgencyAugust 17, 2023 | prnewswire.comEuropean Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic AtrophyJuly 26, 2023 | markets.businessinsider.comEverest Medicines Announces Commercial Launch and First Prescription for XERAVA® in ChinaJuly 11, 2023 | cnbc.comEU expands Wegovy, Ozempic probe over suicide risks to include other weight loss, diabetes drugsJune 26, 2023 | investing.comPoint72/Steven Cohen Increases Stake in Praxis Precision Medicines to 8.9%June 20, 2023 | marketwatch.comDoes Pet Insurance Cover Medication?March 26, 2023 | prnewswire.comEverest Medicines Receives Full Upfront Payment from Gilead for Trodelvy-Related Transaction, Boosting Pro Forma Cash ReservesMarch 19, 2023 | ft.comMedicines regulator seeks to shake off UK ‘isolationist’ label with new allianceMarch 15, 2023 | prnewswire.comBioprojet: WAKIX® (pitolisant) receives approval for the treatment of narcolepsy in children over 6 years of age, a rare, under-diagnosed conditionMarch 12, 2023 | prnewswire.comEverest Medicines Announces Silicon Valley Bank Developments Have Minimal Impact on CompanyMarch 7, 2023 | benzinga.comPharma Mafia Wants To Conquer Cannabis: Can You Patent A Plant? Jazz Is TryingFebruary 28, 2023 | benzinga.comRevolution Medicines' Early-Data Validation For Cancer Program Wins Price Target Boost By This AnalystFebruary 28, 2023 | benzinga.comWhy Revolution Medicines Shares Are Trading Higher TodaySee More Headlines Receive MDCO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/30/2019Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MDCO CUSIP58468810 CIK1113481 Webwww.themedicinescompany.com Phone973-290-6000FaxN/AEmployees62Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,160,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-25.70% Debt Debt-to-Equity Ratio21.45 Current Ratio0.77 Quick Ratio0.77 Sales & Book Value Annual Sales$6.14 million Price / Sales1,102.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.30) per share Price / Book-283.00Miscellaneous Outstanding Shares79,723,000Free FloatN/AMarket Cap$6.77 billion OptionableOptionable Beta1.10 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Mark Timney (Age 54)CEO & Director Mr. Christopher J. Visioli (Age 43)CFO & Treasurer Mr. Stephen M. Rodin J.D. (Age 43)Exec. VP, Gen. Counsel & Sec. Dr. Clive A. Meanwell (Age 61)Chief Innovation Officer & Director Dr. Goutham Krishna GortiVP & Head of Investor RelationsKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZPerrigoNYSE:PRGOCorcept TherapeuticsNASDAQ:CORTCytokineticsNASDAQ:CYTKElanco Animal HealthNYSE:ELANView All Competitors MDCO Stock Analysis - Frequently Asked Questions How were Medicines' earnings last quarter? The Medicines Company (NASDAQ:MDCO) announced its quarterly earnings results on Wednesday, October, 30th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by $0.12. During the same period last year, the company earned ($0.70) EPS. What other stocks do shareholders of Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medicines investors own include Micron Technology (MU), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Salesforce (CRM), Bank of America (BAC), Ionis Pharmaceuticals (IONS), AT&T (T) and Alnylam Pharmaceuticals (ALNY). This page (NASDAQ:MDCO) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Medicines Company Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
